UPCC 20816: Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy (KEYNOTE-199)

UPCC 20816: Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy (KEYNOTE-199)
99 years or below
All
Phase 2
1 Location

Brief description of study

Request for collaborative review: WIRB serving as IRB of record.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: TBD, tbd, tbd
  • Age: 99 years or below
  • Gender: All
Updated on 27 Aug 2018. Study ID: 825773

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.